LFG
NBIX icon

Larson Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Larson Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
1,536
-6
-0.4% -$890 0.01% 745
2026
Q1 		$203K Buy
1,542
+537
+53% +$71.3K 0.01% 715
2025
Q4 		$143K Buy
1,005
+248
+33% +$35.9K ﹤0.01% 804
2025
Q3 		$106K Buy
757
+47
+7% +$6.37K ﹤0.01% 876
2025
Q2 		$89.2K Buy
710
+310
+78% +$35.6K ﹤0.01% 888
2025
Q1 		$44.2K Sell
400
-1,013
-72% -$128K ﹤0.01% 1075
2024
Q4 		$193K Buy
1,413
+12
+0.9% +$1.48K 0.01% 573
2024
Q3 		$161K Sell
1,401
-492
-26% -$67.4K 0.01% 628
2024
Q2 		$261K Sell
1,893
-320
-14% -$43.9K 0.02% 399
2024
Q1 		$305K Sell
2,213
-44
-2% -$6.01K 0.02% 313
2023
Q4 		$297K Buy
2,257
+2,246
+20,418% +$259K 0.03% 273
2023
Q3 		$1.24K Buy
+11
New +$1.16K ﹤0.01% 1455
2023
Q1 		– Sell
-2,331
Closed -$278K – 1586
2022
Q4 		$278K Buy
2,331
+391
+20% +$45.8K 0.03% 257
2022
Q3 		$206K Buy
1,940
+122
+7% +$12.4K 0.03% 267
2022
Q2 		$177K Buy
+1,818
New +$168K 0.03% 204

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Larson Financial Group's NBIX Position: Q2 2026 in Review

Larson Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 0.39% in Q2 2026, selling an estimated $890 and leaving 1,536 shares worth $259K. The position accounts for 0.01% of the portfolio, ranked #745.

Larson Financial Group first reported a position in NBIX in Q2 2022 and has held it in 15 quarters since. The position peaked at $305K in Q1 2024. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Larson Financial Group held 1,536 shares of Neurocrine Biosciences worth $259K as of Q2 2026.
  • Larson Financial Group sold 6 Neurocrine Biosciences shares in Q2 2026, an estimated $890.
  • Neurocrine Biosciences made up 0.01% of Larson Financial Group's portfolio in Q2 2026, its #745 holding.
  • Larson Financial Group first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 15 quarters since.
  • Larson Financial Group's Neurocrine Biosciences position peaked at $305K in Q1 2024.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.